Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06618976 · ClinicalTrials.gov registry record · Phase 4
Antithrombotic Activities of Sotagliflozin vs. Empagliflozin
A Phase 4 study of Thrombosis, sponsored by Icahn School of Medicine at Mount Sinai.
- Active
- Registry status
- Phase 4
- Development phase
- 17
- Enrollment target
- 1
- Study location
NCT06618976 is a Phase 4 study of Thrombosis that is active but no longer recruiting, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 17 participants, below the 470-participant average among 28 other Thrombosis trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06618976, a Phase 4 study of Thrombosis, is active but no longer recruiting, sponsored by Icahn School of Medicine at Mount Sinai.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 17 participants
- Enrollment target
- 1
- Study location
Study Summary
The availability of Sodium-glucose cotransporter-2 inhibitors (SGLT2-i) has dramatically altered the management of heart failure (HF) patients, independently of their ejection fraction and glycemic status. A meta-analysis of 57 studies comparing SGLT2-I monotherapy vs. placebo or active comparator showed reductions in major cardiovascular events, but no impact on atherothrombotic events. In fact, a non-significant increase in the risk for non-fatal stroke was observed. Similar trend observed in multiple trials indicate a SGLT2-i class effect. Sotagliflozin is the first dual SGLT1/2 receptor inhibitor, that was shown to significantly reduce atherothrombotic events compared with placebo in diabetic HF patients, suggesting that dual SGLT1/2 inhibitor may have additional properties vs. SGLT2-i. The hypothesis of this study is that dual SGLT1/2 inhibition by sotagliflozin improves thrombogenic profile (i.e. reduces thrombus formation), which could make it a safer and more effective treatment option for cardiovascular (CV) patients than SGLT2-i. To test the hypothesis, the researchers will compare the antithrombotic activity of sotagliflozin vs. empagliflozin in healthy volunteers using a randomized, cross-over study design, where each participant will receive both study treatments (sotagliflozin and empagliflozin) separated by a washout period. Treatment effects will be assessed by measuring ex vivo thrombus formation using the Badimon Perfusion chamber, platelet aggregation using Multiplate Analyzer, and Thromboelastometry using RoTEM Gamma. Study assessments will be performed before initiating (baseline/pre-treatment) and after completion of each treatment.
Conditions Studied
Interventions
- DRUG Empagliflozin
- DRUG Sotagliflozin
Study Locations (1)
New York
- Icahn School of Medicine at Mount Sinai - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2025-02-25 |
| Est. Completion | 2026-04 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06618976
The ClinicalTrials.gov registry entry for NCT06618976 describes a study currently listed as active not recruiting, categorized as Phase 4. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 470-participant average among 28 other Thrombosis trials with a reported enrollment target (96% lower). The listed sponsor is Icahn School of Medicine at Mount Sinai, which has 708 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Thrombosis appearing as the primary indexed condition, and to 2 interventions - of which Empagliflozin is the first listed.
NCT06618976 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT06618976 about?
NCT06618976 is a clinical study titled "Antithrombotic Activities of Sotagliflozin vs. Empagliflozin". The availability of Sodium-glucose cotransporter-2 inhibitors (SGLT2-i) has dramatically altered the management of heart failure (HF) patients, independently of their ejection fraction and glycemic status. A meta-analysis of 57 studies comparing SGLT2-I monotherapy vs. placebo or active comparator s...
What is the current status of trial NCT06618976?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 17 participants. The study started on 2025-02-25. Estimated completion is 2026-04.
What conditions does trial NCT06618976 study?
This clinical trial studies the following conditions: Thrombosis.
What interventions are being tested in trial NCT06618976?
The interventions under investigation include: Empagliflozin (DRUG), Sotagliflozin (DRUG).
Who is sponsoring clinical trial NCT06618976?
This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06618976 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Thrombosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluation of Argatroban Injection in Pediatric Patients Requiring Anticoagulant Alternatives to Heparin
COMPLETED · Phase 4
-
Apixaban for Secondary Prevention of Thromboembolism Among Patients With AntiphosPholipid Syndrome
COMPLETED · Phase 4
-
ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
RECRUITING
-
Positron Emission Tomography (PET) Imaging of Thrombosis
RECRUITING · Phase 1
-
Pharmacogenomics of Warfarin in Hispanics and Latinos
RECRUITING
-
Neonatal Platelet Transfusion Threshold Trial
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.